METOJECT SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

METHOTREXATE (METHOTREXATE SODIUM)

Dostupno od:

MEDEXUS PHARMACEUTICALS INC.

ATC koda:

L01BA01

INN (International ime):

METHOTREXATE

Doziranje:

10MG

Farmaceutski oblik:

SOLUTION

Sastav:

METHOTREXATE (METHOTREXATE SODIUM) 10MG

Administracija rute:

INTRA-ARTERIAL

Jedinice u paketu:

1ML

Tip recepta:

Prescription

Područje terapije:

ANTINEOPLASTIC AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0107545004; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2020-04-23

Svojstava lijeka

_ _
_Page 1 of _50_ _
PRODUCT MONOGRAPH
Pr
METOJECT
®
methotrexate sodium solution for injection
methotrexate 10 mg/mL
Single-Use Pre-Filled Syringes
Sterile
THERAPEUTIC CLASSIFICATION
Antimetabolite and Antirheumatic
Medexus Inc.
35 Nixon Road, Unit 1
Bolton, Ontario
L7E 1K1
Submission Control No.: 231322
Date of Revision:
December 10, 2019
_ _
_Page 2 of _50_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION .......... Error! Bookmark not
defined.
SUMMARY PRODUCT INFORMATION ..................... ERROR! BOOKMARK NOT
DEFINED.
INDICATIONS AND CLINICAL USE ........................... ERROR!
BOOKMARK NOT DEFINED.
CONTRAINDICATIONS ...............................................
ERROR! BOOKMARK NOT DEFINED.
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS ................................................
ERROR! BOOKMARK NOT DEFINED.
DRUG INTERACTIONS
..............................................................................................
16
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
............................................................................................................
30
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 30
STORAGE AND STABILITY
......................................................................................
33
SPECIAL HANDLING INSTRUCTIONS
....................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 34
PART II: SCIENTIFIC INFORMATION
............................................................................
35
PHARMACEUTICAL INFORMATION
.......................................................................
35
DETAILED PHARMACOLOGY
.................................................................................
36
TOXICOLOGY
.................................................